Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$145.61 USD
+1.83 (1.27%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $145.61 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
SRPT 145.61 +1.83(1.27%)
Will SRPT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SRPT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SRPT
Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 38.04%: Here's is How to Trade
What Makes Sarepta Therapeutics (SRPT) a Strong Momentum Stock: Buy Now?
SRPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
Best Momentum Stocks to Buy for July 3rd
New Strong Buy Stocks for July 3rd
Other News for SRPT
Buy Rating Affirmed for Sarepta Therapeutics Amid Strong Elevidys Demand and Strategic Growth Outlook
Here's How Much $1000 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know.
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)